1473 related articles for article (PubMed ID: 16820546)
1. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
3. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
4. Varenicline: a first-line treatment option for smoking cessation.
Garrison GD; Dugan SE
Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
[TBL] [Abstract][Full Text] [Related]
5. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
7. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad S; Tønnesen P; Hajek P; Williams KE; Billing CB; Reeves KR;
JAMA; 2006 Jul; 296(1):64-71. PubMed ID: 16820548
[TBL] [Abstract][Full Text] [Related]
8. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
West R; Baker CL; Cappelleri JC; Bushmakin AG
Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
[TBL] [Abstract][Full Text] [Related]
9. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
11. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
12. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
13. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.
Ebbert JO; Hatsukami DK; Croghan IT; Schroeder DR; Allen SS; Hays JT; Hurt RD
JAMA; 2014 Jan; 311(2):155-63. PubMed ID: 24399554
[TBL] [Abstract][Full Text] [Related]
14. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Keating GM; Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
[TBL] [Abstract][Full Text] [Related]
15. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Gonzales D; Jorenby DE; Brandon TH; Arteaga C; Lee TC
Addiction; 2010 Nov; 105(11):2002-13. PubMed ID: 20819082
[TBL] [Abstract][Full Text] [Related]
16. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
King DP; Paciga S; Pickering E; Benowitz NL; Bierut LJ; Conti DV; Kaprio J; Lerman C; Park PW
Neuropsychopharmacology; 2012 Feb; 37(3):641-50. PubMed ID: 22048466
[TBL] [Abstract][Full Text] [Related]
17. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
[TBL] [Abstract][Full Text] [Related]
18. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Lindson-Hawley N; Thomas KH; Fanshawe TR; Lancaster T
Cochrane Database Syst Rev; 2016 May; 2016(5):CD006103. PubMed ID: 27158893
[TBL] [Abstract][Full Text] [Related]
19. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
[TBL] [Abstract][Full Text] [Related]
20. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
